Changes in expression of hepatic cytochrome P450 subfamily enzymes during development of adjuvant-induced arthritis in rats

Journal of Toxicological Sciences

Volumn 36, Issue 2, 2011, Pages 181-190

  Sanada, Hisakazu ^a,b   Sekimoto, Masashi ^a   Kamoshita, Ayaka ^a   Degawa, Masakuni ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b KAKEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Adjuvant induced arthritis; CYP3A; Cytochrome P450; Inflammatory cytokine; Rat liver

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2B; CYTOCHROME P450 3A; CYTOKINE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ISOLATION; FOOT PAD; GENE EXPRESSION; INTERMETHOD COMPARISON; LEG SWELLING; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALIA; RATTUS;

EID: 79955383619     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.36.181     Document Type: Article

References (35)

1. Abdel-Razzak, Z., Corcos, L., Fautrel, A. and Guillouzo, A. (1995): Interleukin-1 beta antagonizes phenobarbital induction of several major cytochromes P450 in adult rat hepatocytes in primary culture. FEBS Lett., 366, 159-164.
2. Abraham, S., Begum, S. and Isenberg, D. (2004): Hepatic manifestations of autoimmune rheumatic diseases. Ann. Rheum. Dis., 63, 123-129.
3. Bi, Y., Sun, W.P., Chen, X., Li, M., Liang, H., Cai, M.Y., Zhu, Y.H., He, X.Y., Xu, F. and Weng, J.P. (2008): Effect of early insulin therapy on nuclear factor kappaB and cytokine gene expressions in the liver and skeletal muscle of high-fat diet, streptozotocintreated diabetic rats. Acta Diabetol., 45, 167-178.
4. Burke, M.D., Thompson, S., Weaver, R.J., Wolf, C.R. and Mayer, R.T. (1994): Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem. Pharmacol., 48, 923-936.
5. Cali, J.J., Ma, D., Sobol, M., Simpson, D.J., Frackman, S., Good, T.D., Daily, W.J. and Liu, D. (2006): Luminogenic cytochrome P450 assays. Expert Opin. Drug Metab. Toxicol., 2, 629-645.
6. Clark, M.A., Bing, B.A., Gottschall, P.E. and Williams, J.F. (1995): Differential effect of cytokines on the phenobarbital or 3-methylcholanthrene induction of P450 mediated monooxygenase activity in cultured rat hepatocytes. Biochem. Pharmacol., 49, 97-104.
7. Degawa, M., Tanimura, S., Agatsuma, T. and Hashimoto, Y. (1989): Hepatocarcinogenic heterocyclic aromatic amines that induce cytochrome P-448 isozymes, mainly cytochrome P-448H (P-450IA2), responsible for mutagenic activation of the carcinogens in rat liver. Carcinogenesis, 10, 1119-1122.
8. Fukuda, Y., Ishida, N., Noguchi, T., Kappas, A. and Sassa, S. (1992): Interleukin-6 down regulates the expression of transcripts encoding cytochrome P450 IA1, IA2 and IIIA3 in human hepatoma cells. Biochem. Biophys. Res. Commun., 184, 960-965.
9. Guengerich, F.P. (1999): Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol., 39, 1-17.
10. Guirguis, M.S. and Jamali, F. (2003): Disease-drug interaction: Reduced response to propranolol despite increased concentration in the rat with inflammation. J. Pharm. Sci., 92, 1077-1084.
11. Kadowaki, H., Yamamoto, T., Kageyama-Yahara, N., Kurokawa, N. and Kadowaki, M. (2008): The pathophysiological roles of COX-1 and COX-2 in the intestinal smooth muscle contractility under the anaphylactic condition. Biomed. Res., 29, 113-117.
12. Kojima, M., Ashino, T., Yoshida, T., Iwakura, Y., Sekimoto, M. and Degawa, M. (2009): IL-1 regulates the Cyp7a1 gene and serum total cholesterol level at steady state in mice. Biochem. Biophys. Res. Commun., 379, 239-242.
13. Kojima, M., Sekikawa, K., Nemoto, K. and Degawa, M. (2005): Tumor necrosis factor-alpha-independent downregulation of hepatic cholesterol 7alpha-hydroxylase gene in mice treated with lead nitrate. Toxicol. Sci., 87, 537-542.
14. Kruger, P.S., Freir, N.M., Venkatesh, B., Robertson, T.A., Roberts, M.S. and Jones, M. (2009): A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med., 35, 717-721.
15. Lagueux, J., Affar, E.B., Nadeau, D., Ayotte, P., Dewailly, E. and Poirier, G.G. (1997): A microassay for the detection of low levels of cytochrome P450 O-deethylation activities with alkoxyresorufin substrates. Mol. Cell. Biochem., 175, 125-129.
16. Lin, J.H. and Lu, A.Y. (2001): Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu. Rev. Pharmacol. Toxicol., 41, 535-567.
17. Ling, S. and Jamali, F. (2005): Effect of early phase adjuvant arthritis on hepatic P450 enzymes and pharmacokinetics of verapamil: an alternative approach to the use of an animal model of inflammation for pharmacokinetic studies. Drug Metab. Dispos., 33, 579-586.
18. Ling, S. and Jamali, F. (2009): The effect of infliximab on hepatic cytochrome P450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: a drug-disease and drug-drug interaction. Basic Clin. Pharmacol. Toxicol., 105, 24-29.
19. Lubet, R.A., Mayer, R.T., Cameron, J.W., Nims, R.W., Burke, M.D., Wolff, T. and Guengerich, F.P. (1985): Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat. Arch. Biochem. Biophys., 238, 43-48.
20. Mayo, P.R., Skeith, K., Russell, A.S. and Jamali, F. (2000): Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br. J. Clin. Pharmacol., 50, 605-613.
21. Meyer, U.A. and Zanger, U.M. (1997): Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol., 37, 269-296.
22. Mills, P.R., MacSween, R.N., Dick, W.C., More, I.A. and Watkinson, G. (1980): Liver disease in rheumatoid arthritis. Scott Med. J., 25, 18-22.
23. Morgan, E.T. (1997): Regulation of cytochromes P450 during inflammation and infection. Drug Metab. Rev., 29, 1129-1188.
24. Morgan, E.T. (2001): Regulation of cytochrome P450 by inflammatory mediators: Why and How? Drug Metab. Dispos., 29, 207-212.
25. Newbould, B.B. (1963): Chemotherapy of arthritis induced in rats by mycobacterial adjuvant. Br. J. Pharmacol. Chemother., 21, 127-136.
26. Nyagode, B.A., Lee, C.M. and Morgan, E.T. (2010): Modulation of hepatic cytochrome P450s by citrobacter rodentium infection in interleukin-6-and interferon-γ-null mice. J. Pharmacol. Exp. Ther., 335, 480-488.
27. Omiecinski, C.J., Hassett, C. and Costa, P. (1990): Developmental expression and in situ localization of the phenobarbital-inducible rat hepatic mRNAs for cytochromes CYP2B1, CYP2B2, CYP2C6, and CYP3A1. Mol. Pharmacol., 38, 462-470.
28. Rau, R., Pfenninger, K. and Boni, A. (1975): Proceedings: Liver function tests and liver biopsies in patients with rheumatoid arthritis. Ann. Rheum. Dis., 34, 198-199.
29. Rivory, L.P., Slaviero, K.A. and Clarke, S.J. (2002): Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br. J. Cancer, 87, 277-280.
30. Rosenthale, M.E. (1970): A comparative study of the Lewis and Sprague Dawley rat in adjuvant arthritis. Arch. Int. Pharmacodyn. Ther., 188, 14-22.
31. Schneider, R.E., Bishop, H., Kendall, M.J. and Quarterman, C.P. (1981): Effect of inflammatory disease on plasma concentrations of three beta-adrenoceptor blocking agents. Int. J. Clin. Pharmacol. Ther. Toxicol., 19, 158-162.
32. Scott, D.L., Wolfe, F. and Huizinga, T.W. (2010): Rheumatoid arthritis. Lancet, 376, 1094-1108.
33. Webb, J., Whaley, K., MacSween, R.N., Nuki, G., Dick, W.C. and Buchanan, W.W. (1975): Liver disease in rheumatoid arthritis and Sjogren's syndrome. Prospective study using biochemical and serological markers of hepatic dysfunction. Ann. Rheum. Dis., 34, 70-81.
34. Wilkinson, G.R. (1997): The effects of diet, aging and diseasestates on presystemic elimination and oral drug bioavailability in humans. Adv. Drug Deliv. Rev., 27, 129-159.
35. Yamakawa, J.I., Moriya, J., Takahashi, T., Ishige, A., Motoo, Y., Yoshizaki, F. and Kanda, T. (2010): A Kampo Medicine, Boiogi-to, Inhibits Obesity in Ovariectomized Rats. Evid. Based Complement Alternat. Med., 7, 87-95.